Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
| ▸ | PRKCA | P17252 | 1/20 | 0.30 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18489341 | 0.83 | NOS3 (0.38) | ALDH1A1HTTACHEHSD17B10MEN1 | |
| SCHEMBL377724 | 0.76 | ACHE (0.43) | ALDH1A1HTTABL1ACHEHSD17B10 | |
| SCHEMBL19479982 | 0.73 | ALDH1A1 (0.32) | ALDH1A1HTTPDE2A | |
| SCHEMBL20072446 | 0.71 | PDE2A (0.41) | ALDH1A1PDE2AHSD17B10MEN1GAA | |
| SCHEMBL11595327 | 0.70 | TLR8 (0.41) | MEN1GAAKMT2A | |
| SCHEMBL18525716 | 0.69 | NOS3 (0.39) | ALDH1A1HTTACHEHSD17B10KMT2A | |
| SCHEMBL2747792 | 0.69 | NOS3 (0.39) | ALDH1A1ABL1ACHEHSD17B10MEN1 | |
| SCHEMBL31139293 | 0.69 | ACHE (0.42) | ALDH1A1HTTABL1ACHEHSD17B10 | |
| SCHEMBL11030024 | 0.69 | ACHE (0.42) | ALDH1A1HTTABL1ACHEHSD17B10 | |
| Formic Acid SCHEMBL31038510 | 0.67 | ACHE (0.36) | ALDH1A1HTTACHEHSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11225469-B2 | Inhibitors of phosphoglycerate dehydrogenase (PHGDH) and uses thereof | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2022-01-18 | — | — | US | disclosed |
| US-20180105508-A1 | INHIBITORS OF PHOSPHOGLYCERATE DEHYDROGENASE (PHGDH) AND USES THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11225469-B2 | Inhibitors of phosphoglycerate dehydrogenase (PHGDH) and uses thereof | PHGDH, PGD, PGK1 | ALDH1A1 819/4885HTT 3947/4885PDE2A 2669/4885 |
| US-20180105508-A1 | INHIBITORS OF PHOSPHOGLYCERATE DEHYDROGENASE (PHGDH) AND USES THEREOF | PHGDH, PGD, PGK1 | ALDH1A1 778/4885HTT 4018/4885PDE2A 2377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.